Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.350
+0.030 (2.27%)
At close: Apr 2, 2026, 4:00 PM EDT
1.355
+0.005 (0.37%)
After-hours: Apr 2, 2026, 4:30 PM EDT
Pliant Therapeutics Employees
Pliant Therapeutics had 49 employees as of December 31, 2025. The number of employees decreased by 122 or -71.35% compared to the previous year.
Employees
49
Change (1Y)
-122
Growth (1Y)
-71.35%
Revenue / Employee
n/a
Profits / Employee
-$3,047,837
Market Cap
83.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 49 | -122 | -71.35% |
| Dec 31, 2024 | 171 | 13 | 8.23% |
| Sep 30, 2024 | 166 | 7 | 4.40% |
| Jun 30, 2024 | 166 | 11 | 7.10% |
| Mar 31, 2024 | 158 | 22 | 16.18% |
| Dec 31, 2023 | 158 | 34 | 27.42% |
| Sep 30, 2023 | 159 | 45 | 39.47% |
| Jun 30, 2023 | 155 | 45 | 40.91% |
| Mar 31, 2023 | 136 | 35 | 34.65% |
| Dec 31, 2022 | 124 | 33 | 36.26% |
| Sep 30, 2022 | 114 | 24 | 26.67% |
| Jun 30, 2022 | 110 | 20 | 22.22% |
| Mar 31, 2022 | 101 | 11 | 12.22% |
| Dec 31, 2021 | 91 | 13 | 16.67% |
| Sep 30, 2021 | 90 | 20 | 28.57% |
| Jun 30, 2021 | 90 | 23 | 34.33% |
| Mar 31, 2021 | 90 | 28 | 45.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Gossamer Bio | 162 |
| Rani Therapeutics Holdings | 106 |
| Fortress Biotech | 101 |
| PolyPid | 75 |
| aTyr Pharma | 60 |
| NeurAxis | 24 |
| Filana Therapeutics | 20 |
PLRX News
- 17 days ago - Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - GlobeNewsWire
- 24 days ago - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Stock Picks From Seeking Alpha's February 2026 New Analysts - Seeking Alpha
- 5 weeks ago - Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration - Seeking Alpha
- 5 weeks ago - Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - GlobeNewsWire
- 4 months ago - Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors - Benzinga
- 4 months ago - Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - GlobeNewsWire
- 4 months ago - Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference - GlobeNewsWire